All Drugs and Chemicals

Immunomodulating Agents

Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.

NK cell therapy

Zhenfeng Zhang, MD,PhD

Peng Li, PhD

T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK cell therapy and scheduled to start a clinical phase I study.

One gene can be knockout of the T cells to produce a T-like NK cells which obtain killing function of both T effector cells and NK cells. We will collect appropriate patient's T cells, produce T-like NK cells (ITNK), and infuse the ITNK cells back to the patients to treat various of cancers.

Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression

A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the ITNK cells, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5. Incidence of treatment-emergent adverse events will be calculated as standard methods.

Response rates will be estimated as the percent of patients whose best response is either complete remission or partial remission by combining the data from the patients. To compare with historical data, a 95% confidence interval will be calculated for the response rate.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I	NCT03882840	Anti-cancer Cel... T Cell and NK C...	NK cell therapy	18 Years -	Second Affiliated Hospital of Guangzhou Medical University
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I	NCT03882840	Anti-cancer Cel... T Cell and NK C...	NK cell therapy	18 Years -	Second Affiliated Hospital of Guangzhou Medical University
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I	NCT03882840	Anti-cancer Cel... T Cell and NK C...	NK cell therapy	18 Years -	Second Affiliated Hospital of Guangzhou Medical University

Spots Global Cancer Trial Database for t cell and nk cell